The new web-based tool, TrialMax Web, is set to change the way late phase study teams collect patient data by offering a tailor made solution with important patient usability benefits.
CRF Health announced the release of an innovative online ePRO and patient management solution for global late phase clinical studies, TrialMax Web. Unique in combining PRO data capture with an array of tools that can improve patient compliance and retention, both critical challenges in late phase research, TrialMax Web has been developed to collect data directly from patients more easily and efficiently than any other web-based solution. TrialMax Web contains unique tools that have been developed and tested in cooperation with patients, patient advocacy groups, and industry outcomes research experts.
Rachael King, CEO, notes: “I am delighted to announce the launch of TrialMax Web, our new solution for late phase study teams. We are proud to offer this exciting patient-focused solution to improve results in late phase studies. We believe that TrialMax Web offers an important new option for global phase IV study teams to interact with patients and deliver the highest quality data.”
TrialMax Web allows late phase studies to collect data from patients without purchasing any hardware, since patients can use it on their own computers or smart phones. As TrialMax Web eliminates the need for handling paper, the collection of Patient Reported Outcomes is more cost efficient and also more easily manageable for large studies. Study teams can utilize the data in real time according to the needs of the study. Recognizing that some study sites involved in late phase studies may lack the experience or resources for managing a study, TrialMax Web provides the reassurance of a tested and proven tool.
“Post-approval research is going through a tremendous change at the moment,” comments King. “We appreciate the challenges of conducting studies in the real-world, and look forward to offering study teams a tool that not only provides them with data, but helps them keep patients connected to the study so they can achieve high quality results.”
TrialMax Web, developed with the help of scientific experts, provides comprehensive capabilities for designing and validating PRO instruments across large patient populations. And because the solution was developed as part of the TrialMax® family of ePRO solutions, the portal is fully inter-operable with all our other components. In addition data can be transferred in real-time to other eClinical systems such as EDC via TrialMax Synapse&™, which means that sponsors can manage their study more efficiently.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.